Company Filing History:
Years Active: 2006
Title: The Innovations of Neervalur V Raghavan: A Look into His Patent and Career
Introduction: Neervalur V Raghavan is an accomplished inventor based in Northbrook, IL, recognized for his significant contributions to the field of pharmaceuticals. With a patent to his name, Raghavan has made strides in the development of a specialized parenteral solution that enhances the administration of amiodarone.
Latest Patents: Raghavan's patent, titled "Premixed Amiodarone Parenteral Solution and Method for Making the Same," outlines a novel solution for intravenous administration. The formulation contains amiodarone as the active ingredient, solubilized in water for injection, and supplemented with a non-ionic surfactant ranging from 0.4 to 12 mg/ml. This innovation eliminates the need for dilution before administration, ensuring ease of use for healthcare professionals. The sterile packaged solution maintains a pH between 2.9 and 3.2, with a preferred value of 3.1, which is critical for patient safety and efficacy. The patent also elaborates on a method for producing this amiodarone solution, streamlining its manufacturing process.
Career Highlights: Neervalur V Raghavan is affiliated with Baxter International Inc., a leading company in the healthcare industry dedicated to advancing medical solutions. His work at Baxter has enabled him to push the boundaries of pharmaceutical innovations, particularly in the field of intravenous solutions.
Collaborations: Throughout his career, Raghavan has collaborated with esteemed colleagues, including Mark Joseph Doty and Christine L Rebbeck. These collaborations reflect a shared commitment to enhancing pharmaceutical formulations and improving patient outcomes.
Conclusion: Neervalur V Raghavan's contributions to the pharmaceutical field, particularly through his patent for a premixed amiodarone solution, highlight his innovative approach to medical challenges. His work not only benefits healthcare providers but also significantly improves the quality of care for patients requiring intravenous administration of amiodarone. As he continues his career at Baxter International Inc., Raghavan's future innovations promise to further enhance the landscape of pharmaceutical solutions.